JUNIPER: A Phase 2 Study to Evaluate the Safety Biological Activity and PK of ND-L02-s0201 in Subjects With IPF

  • End date
    Sep 19, 2022
  • participants needed
  • sponsor
    Nitto Denko Corporation
Updated on 8 December 2021
carbon monoxide
forced vital capacity
diffusion capacity of the lung for carbon monoxide


A phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety, tolerability, biological activity, and pharmacokinetics (PK) of ND-L02-s0201 for Injection in subjects with IPF.

Condition Pulmonary Fibrosis, usual interstitial pneumonia, Idiopathic Pulmonary Fibrosis
Treatment ND-L02-s0201, Other: Placebo
Clinical Study IdentifierNCT03538301
SponsorNitto Denko Corporation
Last Modified on8 December 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note